Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
FDA panel unimpressed with data for Alzheimer’s drug aducanumabThe FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors Share XFDA panel unimpressed with data for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/fda-sceptical-on-biogen-eisai-data-for-alzheimers-drug-aducanumab/
Trials and tribulations in Biogen’s Alzheimer’s drug reviewsRegulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate Share XTrials and tribulations in Biogen’s Alzheimer’s drug reviewshttps://pharmaphorum.com/news/trials-and-tribulations-in-biogens-alzheimers-drug-reviews/
Surprise! Biogen says Alzheimer’s drug works after all and will be filedMere months ago Biogen’s Alzheimer’s drug aducanumab was being written off as the latest amyloid-targeting dud. Now, its Share XSurprise! Biogen says Alzheimer’s drug works after all and will be filedhttps://pharmaphorum.com/news/surprise-biogen-says-alzheimers-drug-works-after-all-and-will-be-filed/
A bright future for CNS and Alzheimer’s?Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare Share XA bright future for CNS and Alzheimer’s?https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/
Biogen drug shows potential in Alzheimer’sPhase 1b trial shows aducanumab clears brain plaques. Share XBiogen drug shows potential in Alzheimer’shttps://pharmaphorum.com/news/biogen-drug/